Eyes wide shut at vision journal as retraction notice misses the point

Photo by Steve H.

Molecular Vision appears to have been flying blind when it retracted a 2013 paper by Rajendra Kadam and colleagues.

In December 2018, Kadam, a former “golden boy” in pharmaceutical research at the University of Colorado, Denver, was the subject of a finding from the U.S. Office of Research Integrity, which stated that he had fabricated his data. As part of the agreement, Kadam agreed to retract a paper in Molecular Vision. .

Kadam, who in 2016 had his doctoral degree revoked by UC Denver, two years after the university completed an investigation and sent its finding to the Office of Research Integrity (ORI), now has eight retractions, two expressions of concern and a correction. Seven of them mention fabrication of data. But Molecular Vision, the most recent addition to the list, does not.

The paper was titled “Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes.” Its retraction notice, issued February 18, states: Continue reading Eyes wide shut at vision journal as retraction notice misses the point

Molecular Vision retracts three papers from University of Georgia group with error-ridden images

newmvlogoMolecular Vision has issued “full retractions” for a trio of articles by a group of eye researchers. All of the articles were led by Azza El-Remessy, director of the University of Georgia College of Pharmacy’s clinical and therapeutic graduate program.

As much as that is, there might be more still with this case.

The first paper, from 2000, was titled “Regulation of interphotoreceptor retinoid-binding protein (IRBP) gene expression by cAMP in differentiated retinoblastoma cell.” Its abstract states: Continue reading Molecular Vision retracts three papers from University of Georgia group with error-ridden images